Zura Bio Limited Financials
Financial Health Signals
Zura Bio Limited passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Zura Bio Limited generates $0.54 in operating cash flow (-$28.1M OCF vs -$52.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Zura Bio Limited (ZURA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Zura Bio Limited's EBITDA was -$55.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
Zura Bio Limited generated -$28.2M in free cash flow in fiscal year 2024, representing cash available after capex.
Zura Bio Limited reported -$52.4M in net income in fiscal year 2024. This represents an increase of 13.2% from the prior year.
Zura Bio Limited earned $-0.60 per diluted share (EPS) in fiscal year 2024. This represents an increase of 71.3% from the prior year.
Zura Bio Limited held $176.5M in cash against $0 in long-term debt as of fiscal year 2024.
Zura Bio Limited had 65M shares outstanding in fiscal year 2024. This represents an increase of 49.8% from the prior year.
Zura Bio Limited invested $24.4M in research and development in fiscal year 2024. This represents a decrease of 44.5% from the prior year.
Zura Bio Limited invested $75K in capex in fiscal year 2024, funding long-term assets and infrastructure.
ZURA Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $11.9M+37.3% | $8.7M-16.9% | $10.5M+73.7% | $6.0M+8.8% | $5.5M+54.2% | $3.6M | N/A | $4.0M |
| SG&A Expenses | $7.6M-19.1% | $9.4M+6.6% | $8.8M-33.9% | $13.3M+113.7% | $6.2M+30.0% | $4.8M | N/A | $6.2M |
| Operating Income | -$19.5M-8.1% | -$18.1M+6.2% | -$19.3M+0.3% | -$19.3M-64.3% | -$11.8M-40.3% | -$8.4M | N/A | -$10.2M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$18.0M-12.8% | -$16.0M+8.3% | -$17.4M+15.7% | -$20.7M-100.4% | -$10.3M-33.3% | -$7.7M | N/A | -$8.3M |
| EPS (Diluted) | $-0.21-23.5% | $-0.17+10.5% | $-0.19+26.9% | $-0.26-52.9% | $-0.17-750.0% | $-0.02 | N/A | $-0.18 |
ZURA Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $143.9M-8.8% | $157.8M-8.5% | $172.5M-3.9% | $179.5M-5.3% | $189.5M+109.4% | $90.5M-10.3% | $100.8M-3.6% | $104.6M |
| Current Assets | $142.3M-9.4% | $157.0M-8.6% | $171.7M-3.9% | $178.7M-5.7% | $189.5M+109.4% | $90.5M-10.3% | $100.8M-3.6% | $104.6M |
| Cash & Equivalents | $139.0M-10.0% | $154.5M-9.4% | $170.6M-3.4% | $176.5M-6.3% | $188.4M+109.8% | $89.8M-10.0% | $99.8M-3.9% | $103.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $25.5M+36.3% | $18.7M-11.4% | $21.1M+8.1% | $19.5M+11.9% | $17.4M+7.2% | $16.3M-60.8% | $41.5M+0.3% | $41.4M |
| Current Liabilities | $25.5M+36.3% | $18.7M-11.4% | $21.1M+8.1% | $19.5M+29.5% | $15.1M+2.7% | $14.7M-27.7% | $20.3M+19.3% | $17.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $108.2M-14.0% | $125.9M-8.9% | $138.2M-5.9% | $146.8M-6.2% | $156.5M+156.6% | $61.0M+2.8% | $59.3M-6.1% | $63.2M |
| Retained Earnings | -$207.4M-9.5% | -$189.3M-9.2% | -$173.3M-11.2% | -$155.9M-28.2% | -$121.6M-9.3% | -$111.2M-7.5% | -$103.5M-8.9% | -$95.0M |
ZURA Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$15.4M+3.7% | -$16.0M-44.9% | -$11.1M-2.2% | -$10.8M-63.6% | -$6.6M-32.8% | -$5.0M-22.9% | -$4.1M-57.6% | -$2.6M |
| Capital Expenditures | $32K+113.3% | $15K-69.4% | $49K+8.9% | $45K+350.0% | $10K+42.9% | $7K | N/A | N/A |
| Free Cash Flow | -$15.5M+3.5% | -$16.0M-44.4% | -$11.1M-2.2% | -$10.9M-64.0% | -$6.6M-32.8% | -$5.0M | N/A | N/A |
| Investing Cash Flow | -$32K-113.3% | -$15K+69.4% | -$49K-8.9% | -$45K-350.0% | -$10K+99.8% | -$5.0M | $0+100.0% | -$2.3M |
| Financing Cash Flow | $3K+108.8% | -$34K-100.7% | $5.2M+706.9% | -$854K | N/A | N/A | $0+100.0% | -$4.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ZURA Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -12.5%-2.4pp | -10.1%-0.0pp | -10.1%+0.8pp | -10.9%-5.5pp | -5.5%+3.1pp | -8.6% | N/A | -7.9% |
| Current Ratio | 5.58-2.8 | 8.40+0.3 | 8.14-1.0 | 9.16-3.4 | 12.57+6.4 | 6.17+1.2 | 4.97-1.2 | 6.15 |
| Debt-to-Equity | 0.24+0.1 | 0.150.0 | 0.15+0.0 | 0.13+0.0 | 0.11-0.2 | 0.27-0.4 | 0.70+0.0 | 0.65 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Zura Bio Limited profitable?
No, Zura Bio Limited (ZURA) reported a net income of -$52.4M in fiscal year 2024.
What is Zura Bio Limited's earnings per share (EPS)?
Zura Bio Limited (ZURA) reported diluted earnings per share of $-0.60 for fiscal year 2024. This represents a 71.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Zura Bio Limited's EBITDA?
Zura Bio Limited (ZURA) had EBITDA of -$55.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Zura Bio Limited's free cash flow?
Zura Bio Limited (ZURA) generated -$28.2M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Zura Bio Limited's operating cash flow?
Zura Bio Limited (ZURA) generated -$28.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Zura Bio Limited's total assets?
Zura Bio Limited (ZURA) had $179.5M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Zura Bio Limited's capital expenditures?
Zura Bio Limited (ZURA) invested $75K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Zura Bio Limited spend on research and development?
Zura Bio Limited (ZURA) invested $24.4M in research and development during fiscal year 2024.
How many shares does Zura Bio Limited have outstanding?
Zura Bio Limited (ZURA) had 65M shares outstanding as of fiscal year 2024.
What is Zura Bio Limited's current ratio?
Zura Bio Limited (ZURA) had a current ratio of 9.16 as of fiscal year 2024, which is generally considered healthy.
What is Zura Bio Limited's debt-to-equity ratio?
Zura Bio Limited (ZURA) had a debt-to-equity ratio of 0.13 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Zura Bio Limited's return on assets (ROA)?
Zura Bio Limited (ZURA) had a return on assets of -29.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Zura Bio Limited's cash runway?
Based on fiscal year 2024 data, Zura Bio Limited (ZURA) had $176.5M in cash against an annual operating cash burn of $28.1M. This gives an estimated cash runway of approximately 75 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Zura Bio Limited's Piotroski F-Score?
Zura Bio Limited (ZURA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Zura Bio Limited's earnings high quality?
Zura Bio Limited (ZURA) has an earnings quality ratio of 0.54x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.